Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro.
Antimicrobial peptides (AMPs) are a diverse group of proteinaceous compounds ranging in size, complexity and antimicrobial spectrum. The activity of AMPs against gut pathogens warrants the study of the interaction of AMPs with the mammalian gastrointestinal tract. In particular, the investigation of the in vitro cytotoxicity of these peptides is critical before they can be considered in clinical infections. The cytotoxicity of gallidermin, nisin A, natural magainin peptides, and melittin was investigated in two gastrointestinal cell models (HT29 and Caco-2) with the MTT conversion assay, neutral red dye uptake assay and compared with that of vancomycin. The hemolytic activities were also investigated in sheep erythrocytes and the effect of AMPs on paracellular permeability was examined by transepithelial resistance (TEER) and TEM. Gallidermin was the least cytotoxic AMP followed by nisin A, magainin I, magainin II and melittin. Melittin and nisin were the only peptides to result in significant hemolysis. However, while nisin caused hemolysis at concentrations which were 1000-fold higher than those required for antimicrobial activity, melittin was hemolytic at concentrations in the same order of magnitude as its antimicrobial activity. Melittin was the only AMP to affect paracellular permeability. Long term melittin treatment also resulted in loss of microvilli, an increase in cell debris and destruction of intestinal tight junctions and cell-cell adhesion. Gallidermin shows most promise as a therapeutic agent, with relatively low cytotoxicity and potent antimicrobial activities. Melittin, while showing little potential as an antimicrobial agent, may have potential in delivery of poorly bioavailable drugs.
Maher
Sam
S
Institute of Technology Tallaght Dublin, Old Blessington Road, Tallaght, Dublin 24, Republic of Ireland. x00004464@itnet.ie
McClean
Siobhán
S
D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity; D023181:Antimicrobial Cationic Peptides / Q000633:toxicity*; D001430:Bacteriocins / Q000633:toxicity*; D018938:Caco-2 Cells; D002462:Cell Membrane / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004847:Epithelial Cells / Q000187:drug effects*; D004912:Erythrocytes / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D019073:HT29 Cells; D006461:Hemolysis; D006801:Humans; D007422:Intestines / Q000166:cytology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D054806:Magainins; D008555:Melitten / Q000633:toxicity; D016982:Micrococcus luteus / Q000187:drug effects; D046529:Microscopy, Electron, Transmission; D009561:Nisin / Q000633:toxicity*; D010455:Peptides / Q000633:toxicity*; D012756:Sheep; D014640:Vancomycin / Q000494:pharmacology; D029867:Xenopus Proteins / Q000633:toxicity*
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001430:Bacteriocins; D054806:Magainins; D010455:Peptides; D029867:Xenopus Proteins; C053301:magainin 2 peptide, Xenopus; C053300:magainin 1 peptide, Xenopus; C057656:gallidermin; D009561:Nisin; D008555:Melitten; D014640:Vancomycin; D007770:L-Lactate Dehydrogenase; C102526:nisin A